Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation Authors: Tiantian Hu, Wenli Zhang, Teng Zhang, Man Wang, Zongxuan Huang, Yanling Tao Published: 2026 ABSTRACT According to the 2016 World Health Organization classifcation, a germline DEAD-box helicase 41 gene (DDX41) mutation with myeloid neoplasms(MNs) has been newly classifed. Such mutations are clearly linked to late-onset MNs, with patients typically presenting in middle to old age and often manifesting as high-risk AML or MDS. These patients are sensitive to hypomethylating agents, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently recognized as the curative treatment modality. However, pediatric cases of MNs associated with germline DDX41 mutations are extremely rare, resulting in significant gaps in understanding their clinical characteristics, treatment strategies, and prognostic data. This article reports a pediatric patient with high-risk myelodysplastic syndrome (MDS-EB-2) associated with a germline DDX41 mutation (c.316_320del) who underwent unrelated cord blood allogeneic hematopoietic stem cell transplantation. An 8-year-old female patient achieved bone marrow remission with azacitidine and venetoclax and subsequently underwent allogeneic hematopoietic stem cell transplantation from an unrelated umbilical cord blood donor, The conditioning regimen included fludarabine, decitabine, busulfan, and cyclophosphamide, leading to sustained donor engraftment. Post-transplant complications included HHV-6 encephalitis and grade III acute graft-versus-host disease (aGVHD) of the skin and gut, which were managed and controlled. At the 13-month follow-up, the patient remained in complete hematologic remission without recurrence. This case suggests that allo-HSCT is a feasible curative option for children with high-risk MDS and germline DDX41 predisposition, highlighting the critical importance of screening potential donors for the same mutation. Introduction A significant update in the 2016 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues was the inclusion of “myeloid neoplasms with germline predisposition (MNGPs)” as a distinct category. Within this classification, DDX41 is one of the most common germline predisposition loci. Compared to other myeloid malignancy predisposition genes, DDX41 mutations are associated with a significantly older age of onset, with a median diagnostic age of over 60 years [1–3], and are appreciated as the most common cause of germline predisposition to adult myeloid malignancies. These patients also exhibit distinct clinical features: high-risk MDS/AML at presentation, strong male bias, and normal cytogenetics without additional molecular markers. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment strategy, particularly for young patients in good clinical condition. While numerous studies have focused on adult patients, pediatric cases are rare, and related treatment experience is lacking. This report describes a pediatric case of high-risk MDS with germline DDX41 predisposition and focuses on transplant-related clinical decision-making and post-transplant challenges, which remain underrepresented in pediatric literature. Case presentation An 8-year-old female was admitted in early October 2024 following the identification of cytopenia. Physical examination was unremarkable except for signs of anemia, with no significant past medical or family history. Bone marrow cytology revealed hypercellular marrow with 18% myeloid blasts. The blasts exhibited loose chromatin and visible nucleoli. Dysplasia was observed in all three lineages: granulocytic, erythroid, and megakaryocytic (Fig. 1). Flow cytometric analysis identified an abnormal myeloid blast population accounting for 10.1% of nucleated cells, The blasts were positive for cMPO, CD117, CD38 (78.86%), CD33, CD13 (dim), and HLA-DR. Bone marrow biopsy showed hypercellular marrow with abundant immature cells and blasts; the megakaryocyte count was increased, featuring small forms with hypolobated nuclei. Immunohistochemistry was positive for CD34+ and CD117+, with mononuclear megakaryocytes noted. Leukemia fusion gene testing was negative. Karyotype Analysis: 46,XX [20]. Based on these findings, the patient was diagnosed with Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2). Fig. 1The presentationof bone marrow morpholoy. (a) Hypercellular bone marrow. ༈b༉Myeloid blasts account for 18%, exhibiting loose chromatin and visible nucleoli. ༈c༉Granulocytic dysplasia with hypogranular cytoplasm. The left panel shows a ring-nucleated granulocyte, and the right panel shows pseudo-Pelger-Huët anomaly;༈d༉Dysplasia of the erythrocytic lineage accounting for 10.1%. The left panel shows a binucleated erythrocyte, the middle panel shows nuclear budding, and the right panel shows a petal-nucleated erythrocyte. ༈e༉Dysplasia of megakaryocytes. The leftmost panel shows a small megakaryocyte, the middle panel shows a multinucleated megakaryocyte, and the rightmost panel shows a binucleated megakaryocyte The presentationof bone marrow morpholoy. (a) Hypercellular bone marrow. ༈b༉Myeloid blasts account for 18%, exhibiting loose chromatin and visible nucleoli. ༈c༉Granulocytic dysplasia with hypogranular cytoplasm. The left panel shows a ring-nucleated granulocyte, and the right panel shows pseudo-Pelger-Huët anomaly;༈d༉Dysplasia of the erythrocytic lineage accounting for 10.1%. The left panel shows a binucleated erythrocyte, the middle panel shows nuclear budding, and the right panel shows a petal-nucleated erythrocyte. ༈e༉Dysplasia of megakaryocytes. The leftmost panel shows a small megakaryocyte, the middle panel shows a multinucleated megakaryocyte, and the rightmost panel shows a binucleated megakaryocyte HSCT was planned. Human leukocyte antigen (HLA) testing of the father, younger sister, and younger brother revealed all were haploidentical matches. Due to the brother’s young age (2 months old) and the family’s refusal to use the sister as the donor, the father was initially selected. However, during the preparation, next-generation sequencing (NGS) of the bone marrow sample identified a frameshift mutation in DDX41 (NM_016222.4: c.316_320del, p.Lys106Glu fs27; VAF 42.6%) and a missense mutation in IDH1 (NM_005896.4: c.395G > A, p.Arg132His; VAF 1.10%). Subsequent analysis of non-hematopoietic specimens (fingernails) confirmed that the DDX41 variant was of germline origin (Fig. 2a). The transplant procedure was urgently suspended, and genetic screening was performed on family members. Pedigree screening confirmed that the patient’s father and younger brother both carried this variant, while her mother and younger sister did not (Fig. 2b-e). After excluding the father and brother as potential donors, a search for an unrelated donor was initiated through bone marrow and cord blood banks. As bridging therapy during the search, the patient received azacitidine combined with venetoclax chemotherapy (Fig. 3). Eventually, a suitable donor was identified in a cord blood bank (8/10 HLA match, with mismatches at the A and B loci). The patient underwent a conditioning regimen of fludarabine /decitabine /busulfan /cyclophosphamide and received an unrelated umbilical cord blood stem cell transplant on November 20 (TNC 3.44 × 10⁷/kg, CD34⁺ 2.33 × 10⁵/kg), Neutrophil engraftment occurred on day 16, and platelet engraftment on day 38(Fig. 4a). GVHD prophylaxis consisted of oral tacrolimus initiated on day − 1 (1 mg twice daily; 0.08 mg/kg/day), with a target trough concentration of 5–10 ng/mL, and mycophenolate mofetil initiated on day + 1 at a dose of 0.25 g twice daily (20 mg/kg/day), Mycophenolate mofetil levels were not routinely monitored. Infection prophylaxis was initiated at the start of conditioning (day − 8) and included voriconazole for antifungal prophylaxis and acyclovir (10 mg/kg every 8 h) for antiviral prophylaxis. Fig. 2Sanger Sequencing Chromatograms of the DDX41 Gene in the Proband’s Family. (a) proband, pediatric patient. (b) proband’s father. (c) proband’s younger brother. (d) proband’s mother. (e) proband’s younger sister Sanger Sequencing Chromatograms of the DDX41 Gene in the Proband’s Family. (a) proband, pediatric patient. (b) proband’s father. (c) proband’s younger brother. (d) proband’s mother. (e) proband’s younger sister Fig. 3Clinical course of azacitidine and venetoclax treatment. AZA, azacitidine; VEN, venetoclax Clinical course of azacitidine and venetoclax treatment. AZA, azacitidine; VEN, venetoclax Fig. 4Clinical course after allogeneic hematopoietic stemell transpl cantation. FLU, fludarabine; DAC, Decitabine; BU, busulfan; CTX, cyclophosphamide; HSV-6E, human herpesvirus 6 encephalitis; GCV, ganciclovir; CDV, cidofovir; MP, methylprednisolone; RUX, ruxolitinib Clinical course after allogeneic hematopoietic stemell transpl cantation. FLU, fludarabine; DAC, Decitabine; BU, busulfan; CTX, cyclophosphamide; HSV-6E, human herpesvirus 6 encephalitis; GCV, ganciclovir; CDV, cidofovir; MP, methylprednisolone; RUX, ruxolitinib On day 24, the patient developed symptoms including apathy, intermittent irritability, hypertension, and significant hyponatremia. Despite antihypertensive treatment and correction of hyponatremia, the patient rapidly developed limb weakness and urinary retention, followed by frequent convulsions the next day. MRI revealed swelling and abnormal signals in parts of the cerebral gyri in the left temporal lobe and hippocampus. NGS of cerebrospinal fluid (CSF) detected 113,620 sequence reads of human herpesvirus 6 (HHV-6), confirming a diagnosis of HHV-6 encephalitis. Antiviral therapy was initiated immediately with foscarnet and ganciclovir, later switched to cidofovir, and combined with intravenous immunoglobulin (IVIG). After approximately 4 weeks of treatment, follow-up CSF NGS showed HHV-6 DNA copy number had decreased to 0 copies/mL. Although GVHD prophylaxis with tacrolimus and mycophenolate mofetil was administered post-transplant, the patient developed stage Ⅲ acute skin GVHD on day 33, which was subsequently treated with methylprednisolone for immunosuppression (2 mg/kg/day from day + 33 to + 40, followed by gradual tapering). On day 35, stage Ⅲ acute intestinal GVHD emerged, ruxolitinib(5 mg twice daily from day + 35 to day + 69) and a single dose of basiliximab (10 mg on day + 40) were added. The patient’s condition improved with this treatment, allowing for the gradual discontinuation of methylprednisolone and ruxolitinib phosphate. However, on day 75, stageⅡacute skin GVHD recurred, which was rapidly relieved after re-administration of methylprednisolone (Fig. 4b). During the 13-month follow-up after allo-HSCT, the patient had no recurrence of GVHD. Minimal residual disease (MRD) was serially assessed by bone marrow examination at days + 29, +96, + 196, +263, and + 380 post-transplantation. MRD remained consistently negative (< 10⁻⁴) at all evaluated timepoints, with no detection of the IDH1 mutation. Regarding neurological symptoms, a follow-up cranial MRI in October 2025 indicated normalization of the left temporal lobe and hippocampal structures, with disappearance of abnormal signal intensities. EEG demonstrated slow waves in the left parietal, occipital, and mid-posterior temporal regions. The patient currently continues oral administration of valproate sodium and levetiracetam, which effectively controls epileptic seizures. She exhibits no motor deficits, communicates effectively, but has persistent mild memory impairment and occasional behavioral abnormalities. Discussion and conclusion The management of myeloid neoplasms (MNs) varies with age. In contrast to MDS in older adults, therapeutic strategies for children and adolescents with MDS are generally curative [4]. Particularly for MDS with underlying germline predisposition, early hematopoietic stem cell transplantation is standard of care. According to the American College of Medical Genetics and Genomics (ACMG) guidelines, the germline DDX41 frameshift variant was classified as pathogenic, based on its predicted loss-of-function effect in a gene where such variants are a known disease mechanism (PVS1), absence or extremely low frequency in population databases (PM2), and previous reports linking similar variants to myeloid neoplasms with germline predisposition. The present case does not represent an unprecedented entity but rather provides a pediatric perspective on established disease biology and transplant principles. However, existing literature on the application of allo-HSCT in DDX41-mutated MNs is limited, primarily focused on adult patients, and has yielded conflicting results. Wan et al. [5] reported a post-transplantation relapse rate of only 8% among 39 DDX41-mutated patients, which is lower than rates reported in previous studies [6, 7]. Duployez et al. [8] reported significant prolonged relapse-free survival (5-year CI of relapse was 16%) but didn’t report longer overall survival. Kambara et al. [9] reported that among 16 cases of very late relapse after transplantation for AML/MDS, six were positive for DDX41 mutation, making it the most frequently mutated gene in their cohort. Saygin et al. [10] observed that patients with DDX41 germline mutations were more susceptible to severe GVHD after HSCT, which adversely affected survival. A study by Bataller et al. indicated that among patients with DDX41-mutated MNs, overall survival (OS) was similar regardless of whether they received chemotherapy or HSCT [11]. In summary, the long-term outcomes of HSCT and their relationship with non-relapse mortality (NRM) have not yet been fully elucidated. Beyond HSCT, multiple studies have shown that treatment with standard chemotherapy or hypomethylating agents(HMAs) is more likely to induce disease remission in DDX41-mutated cases compared to patients without DDX41 mutations, and relapse is less common in these patients [2, 8, 12]. Furthermore, a study by Bataller et al. first explored the role of the Bcl-2 inhibitor venetoclax in treating such patients [11]. The results demonstrated that patients who received low-intensity therapy (LIT) combined with venetoclax had significantly improved remission and survival rates compared with those who received LIT alone. Wang et al. [13] showed that venetoclax combined with the hypomethylating agent azacitidine is effective in DDX41-mutated MDS patients, especially treatment-naive ones. Although no consensus guidelines currently exist for the clinical management of DDX41-mutated MDS/AML, relevant treatment strategies have emerged in clinical practice: fit patients eligible for intensive chemotherapy receive standard induction therapy, followed by allogeneic HSCT during remission at the earliest opportunity [8, 11]. For patient ineligible for transplantation or who cannot tolerate intensive chemotherapy, less intensive regimens based on hypomethylating agents or LIT combined with venetoclax represent viable options [2, 11, 13]. In this case, an allogeneic stem cell donor had not been identified initially, so we administered venetoclax combined with azacitidine chemotherapy during the waiting period. The child tolerated this regimen well without significant myelosuppression or severe infections and successfully achieved complete remission. This suggests that venetoclax combined with azacitidine may also be an effective treatment option for pediatric MDS patients when HSCT is not immediately feasible. The patient in this report is an 8-year-old child diagnosed with high-risk myelodysplastic syndrome with excess blasts (MDS-EB), presenting a clear indication for allo-HSCT. However, clinical experience regarding HSCT in pediatric myeloid neoplasms harboring germline DDX41 mutations remains limited. Critical aspects of the treatment pathway_including conditioning regimen optimization, donor selection, complication management, and efficacy evaluation_require further investigation. The. Key experiences from this case are summarized as follows: Donor Selection Berger et al. [14] first reported a case of donor cell leukemia caused by a DDX41 mutation. Subsequent studies have further examined the impact of clonal hematopoiesis in donors on HSCT outcomes, indicating that avoiding stem cell sources from donors with germline DDX41 mutations may serve as a strategy to reduce post-transplant relapse risk [15]. Accordingly, the patient’s father, a DDX41 mutation carrier, was excluded as a donor, and unrelated umbilical cord blood was ultimately selected. Importantly, our donor selection strategy is consistent with recent transplant-specific guidance on germline predisposition in myelodysplastic syndromes. The EBMT Chronic Malignancies Working Party position paper [16] recommends systematic evaluation for inherited myeloid malignancy predisposition in patients with suggestive clinical or genetic features and explicitly advises against the use of related donors who harbor pathogenic germline variants in predisposition genes such as DDX41. This consensus underscores the critical importance of genetic screening of potential donors and supports the clinical decision-making applied in the present case.Conditioning Regimen Given the favorable responses to HMAs in patients with MNs harboring germline DDX41 mutations, the conditioning regimen consisted of the classic myeloablative busulfan/cyclophosphamide/fludarabine (BU/Cy/Flu) protocol augmented with decitabine. Decitabine was added to the BU/Cy/Flu conditioning regimen based on its established efficacy in high-risk MDS, its immunomodulatory properties, and emerging evidence supporting its safety and potential benefit when incorporated into myeloablative conditioning regimens for MDS and AML, including in the setting of umbilical cord blood transplantation [17–19]. In addition, prior studies have suggested heightened sensitivity of DDX41-mutated myeloid neoplasms to hypomethylating agents [12], providing further rationale for its inclusion in this patient. Subsequently, successful donor engraftment and complete hematopoietic reconstitution were achieved following transplantation.Prevention and treatment of GVHD The patient developed grade Ⅲ aGVHD involving the skin and gastrointestinal tract, which required combination immunosuppressive therapy to achieve control. However, studies have reported that post-transplant cyclophosphamide can significantly reduce the risk of severe GVHD [10, 11].Management of Complications Despite receiving acyclovir prophylaxis both before and after transplantation, the patient developed severe human herpesvirus 6 (HHV-6) encephalitis, resulting in persistent neurological sequelae. Notably, acyclovir does not provide antiviral coverage against HHV-6. HHV-6 is an opportunistic pathogen, with reported infection rates of approximately 30–50% in allogeneic HSCT recipients, and an even higher incidence in umbilical cord blood transplantation (UCBT) [20–22]. UCB recipients are particularly susceptible due to delayed neutrophil recovery, slow immune reconstitution, and a higher burden of early infectious complications [21, 23]. In addition, previous studies have shown that GVHD prophylaxis with mycophenolate mofetil combined with calcineurin inhibitors may further increase the risk of HHV-6 encephalitis, likely owing to profound and prolonged immunosuppression [23]. In the present case, the use of UCB as the donor source, MMF plus tacrolimus for GVHD prophylaxis, and the lack of HHV-6 coverage by acyclovir collectively represent well-recognized risk factors for HHV-6 encephalitis. DDX41 encodes a DEAD-box RNA helicase involved in pre-mRNA splicing, ribosome biogenesis [24, 25], and innate immune signaling pathways [26, 27]. However, in the present case, no comprehensive immune reconstitution analyses (such as lymphocyte subset recovery), longitudinal HHV-6 viral load monitoring beyond the acute phase or testing to exclude chromosomally integrated HHV-6 were performed. Therefore, a causal relationship between germline DDX41 dysfunction and the development of severe HHV-6 encephalitis cannot be established. Further validation through larger clinical cohort studies is warranted. If confirmed, this association would provide a theoretical basis for developing individualized treatment strategies for patients carrying such mutations, such as enhanced viral monitoring, prolonged antiviral prophylaxis, or earlier initiation of preventive therapy. Beyond infectious complications, impaired immune reconstitution after HSCT has also been implicated in an increased risk of disease relapse. A recent analysis [28] highlighted that delayed or dysfunctional immune recovery following transplantation may compromise graft-versus-leukemia effects, thereby favoring relapse in malignant diseases. In this context, immune vulnerability after HSCT represents a dual risk, predisposing patients not only to opportunistic infections such as HHV-6 encephalitis but also to suboptimal long-term disease control. This underscores the importance of close immune monitoring and individualized immunosuppressive strategies in high-risk patients. Importantly, germline DDX41 predisposition is currently understood to be restricted to hematologic disease and, unlike certain other hereditary cancer syndromes, has not been associated with extrahematological manifestations. Donor Selection Berger et al. [14] first reported a case of donor cell leukemia caused by a DDX41 mutation. Subsequent studies have further examined the impact of clonal hematopoiesis in donors on HSCT outcomes, indicating that avoiding stem cell sources from donors with germline DDX41 mutations may serve as a strategy to reduce post-transplant relapse risk [15]. Accordingly, the patient’s father, a DDX41 mutation carrier, was excluded as a donor, and unrelated umbilical cord blood was ultimately selected. Importantly, our donor selection strategy is consistent with recent transplant-specific guidance on germline predisposition in myelodysplastic syndromes. The EBMT Chronic Malignancies Working Party position paper [16] recommends systematic evaluation for inherited myeloid malignancy predisposition in patients with suggestive clinical or genetic features and explicitly advises against the use of related donors who harbor pathogenic germline variants in predisposition genes such as DDX41. This consensus underscores the critical importance of genetic screening of potential donors and supports the clinical decision-making applied in the present case. Donor Selection Berger et al. [14] first reported a case of donor cell leukemia caused by a DDX41 mutation. Subsequent studies have further examined the impact of clonal hematopoiesis in donors on HSCT outcomes, indicating that avoiding stem cell sources from donors with germline DDX41 mutations may serve as a strategy to reduce post-transplant relapse risk [15]. Accordingly, the patient’s father, a DDX41 mutation carrier, was excluded as a donor, and unrelated umbilical cord blood was ultimately selected. Importantly, our donor selection strategy is consistent with recent transplant-specific guidance on germline predisposition in myelodysplastic syndromes. The EBMT Chronic Malignancies Working Party position paper [16] recommends systematic evaluation for inherited myeloid malignancy predisposition in patients with suggestive clinical or genetic features and explicitly advises against the use of related donors who harbor pathogenic germline variants in predisposition genes such as DDX41. This consensus underscores the critical importance of genetic screening of potential donors and supports the clinical decision-making applied in the present case. Conditioning Regimen Given the favorable responses to HMAs in patients with MNs harboring germline DDX41 mutations, the conditioning regimen consisted of the classic myeloablative busulfan/cyclophosphamide/fludarabine (BU/Cy/Flu) protocol augmented with decitabine. Decitabine was added to the BU/Cy/Flu conditioning regimen based on its established efficacy in high-risk MDS, its immunomodulatory properties, and emerging evidence supporting its safety and potential benefit when incorporated into myeloablative conditioning regimens for MDS and AML, including in the setting of umbilical cord blood transplantation [17–19]. In addition, prior studies have suggested heightened sensitivity of DDX41-mutated myeloid neoplasms to hypomethylating agents [12], providing further rationale for its inclusion in this patient. Subsequently, successful donor engraftment and complete hematopoietic reconstitution were achieved following transplantation. Conditioning Regimen Given the favorable responses to HMAs in patients with MNs harboring germline DDX41 mutations, the conditioning regimen consisted of the classic myeloablative busulfan/cyclophosphamide/fludarabine (BU/Cy/Flu) protocol augmented with decitabine. Decitabine was added to the BU/Cy/Flu conditioning regimen based on its established efficacy in high-risk MDS, its immunomodulatory properties, and emerging evidence supporting its safety and potential benefit when incorporated into myeloablative conditioning regimens for MDS and AML, including in the setting of umbilical cord blood transplantation [17–19]. In addition, prior studies have suggested heightened sensitivity of DDX41-mutated myeloid neoplasms to hypomethylating agents [12], providing further rationale for its inclusion in this patient. Subsequently, successful donor engraftment and complete hematopoietic reconstitution were achieved following transplantation. Prevention and treatment of GVHD The patient developed grade Ⅲ aGVHD involving the skin and gastrointestinal tract, which required combination immunosuppressive therapy to achieve control. However, studies have reported that post-transplant cyclophosphamide can significantly reduce the risk of severe GVHD [10, 11]. Prevention and treatment of GVHD The patient developed grade Ⅲ aGVHD involving the skin and gastrointestinal tract, which required combination immunosuppressive therapy to achieve control. However, studies have reported that post-transplant cyclophosphamide can significantly reduce the risk of severe GVHD [10, 11]. Management of Complications Despite receiving acyclovir prophylaxis both before and after transplantation, the patient developed severe human herpesvirus 6 (HHV-6) encephalitis, resulting in persistent neurological sequelae. Notably, acyclovir does not provide antiviral coverage against HHV-6. HHV-6 is an opportunistic pathogen, with reported infection rates of approximately 30–50% in allogeneic HSCT recipients, and an even higher incidence in umbilical cord blood transplantation (UCBT) [20–22]. UCB recipients are particularly susceptible due to delayed neutrophil recovery, slow immune reconstitution, and a higher burden of early infectious complications [21, 23]. In addition, previous studies have shown that GVHD prophylaxis with mycophenolate mofetil combined with calcineurin inhibitors may further increase the risk of HHV-6 encephalitis, likely owing to profound and prolonged immunosuppression [23]. In the present case, the use of UCB as the donor source, MMF plus tacrolimus for GVHD prophylaxis, and the lack of HHV-6 coverage by acyclovir collectively represent well-recognized risk factors for HHV-6 encephalitis. DDX41 encodes a DEAD-box RNA helicase involved in pre-mRNA splicing, ribosome biogenesis [24, 25], and innate immune signaling pathways [26, 27]. However, in the present case, no comprehensive immune reconstitution analyses (such as lymphocyte subset recovery), longitudinal HHV-6 viral load monitoring beyond the acute phase or testing to exclude chromosomally integrated HHV-6 were performed. Therefore, a causal relationship between germline DDX41 dysfunction and the development of severe HHV-6 encephalitis cannot be established. Further validation through larger clinical cohort studies is warranted. If confirmed, this association would provide a theoretical basis for developing individualized treatment strategies for patients carrying such mutations, such as enhanced viral monitoring, prolonged antiviral prophylaxis, or earlier initiation of preventive therapy. Beyond infectious complications, impaired immune reconstitution after HSCT has also been implicated in an increased risk of disease relapse. A recent analysis [28] highlighted that delayed or dysfunctional immune recovery following transplantation may compromise graft-versus-leukemia effects, thereby favoring relapse in malignant diseases. In this context, immune vulnerability after HSCT represents a dual risk, predisposing patients not only to opportunistic infections such as HHV-6 encephalitis but also to suboptimal long-term disease control. This underscores the importance of close immune monitoring and individualized immunosuppressive strategies in high-risk patients. Importantly, germline DDX41 predisposition is currently understood to be restricted to hematologic disease and, unlike certain other hereditary cancer syndromes, has not been associated with extrahematological manifestations. Management of Complications Despite receiving acyclovir prophylaxis both before and after transplantation, the patient developed severe human herpesvirus 6 (HHV-6) encephalitis, resulting in persistent neurological sequelae. Notably, acyclovir does not provide antiviral coverage against HHV-6. HHV-6 is an opportunistic pathogen, with reported infection rates of approximately 30–50% in allogeneic HSCT recipients, and an even higher incidence in umbilical cord blood transplantation (UCBT) [20–22]. UCB recipients are particularly susceptible due to delayed neutrophil recovery, slow immune reconstitution, and a higher burden of early infectious complications [21, 23]. In addition, previous studies have shown that GVHD prophylaxis with mycophenolate mofetil combined with calcineurin inhibitors may further increase the risk of HHV-6 encephalitis, likely owing to profound and prolonged immunosuppression [23]. In the present case, the use of UCB as the donor source, MMF plus tacrolimus for GVHD prophylaxis, and the lack of HHV-6 coverage by acyclovir collectively represent well-recognized risk factors for HHV-6 encephalitis. DDX41 encodes a DEAD-box RNA helicase involved in pre-mRNA splicing, ribosome biogenesis [24, 25], and innate immune signaling pathways [26, 27]. However, in the present case, no comprehensive immune reconstitution analyses (such as lymphocyte subset recovery), longitudinal HHV-6 viral load monitoring beyond the acute phase or testing to exclude chromosomally integrated HHV-6 were performed. Therefore, a causal relationship between germline DDX41 dysfunction and the development of severe HHV-6 encephalitis cannot be established. Further validation through larger clinical cohort studies is warranted. If confirmed, this association would provide a theoretical basis for developing individualized treatment strategies for patients carrying such mutations, such as enhanced viral monitoring, prolonged antiviral prophylaxis, or earlier initiation of preventive therapy. Beyond infectious complications, impaired immune reconstitution after HSCT has also been implicated in an increased risk of disease relapse. A recent analysis [28] highlighted that delayed or dysfunctional immune recovery following transplantation may compromise graft-versus-leukemia effects, thereby favoring relapse in malignant diseases. In this context, immune vulnerability after HSCT represents a dual risk, predisposing patients not only to opportunistic infections such as HHV-6 encephalitis but also to suboptimal long-term disease control. This underscores the importance of close immune monitoring and individualized immunosuppressive strategies in high-risk patients. Importantly, germline DDX41 predisposition is currently understood to be restricted to hematologic disease and, unlike certain other hereditary cancer syndromes, has not been associated with extrahematological manifestations. This study reports on a case of pediatric MDS with a germline DDX41 variant treated with allo-HSCT. The patient achieved hematological remission and has remained relapse-free during 13 months of follow-up, suggesting that allo-HSCT may be a viable therapeutic option for this patient population. Nevertheless, limitations include the single-case nature and relatively short follow-up period. Future multi-center, large-scale prospective studies are urgently needed to systematically collect pediatric case data, further investigate the pathogenic role of germline DDX41 mutations in childhood myeloid neoplasms, and optimize therapeutic strategies to improve outcomes for thesepatients. Beyond representing pediatric occurrence, this case highlights practical considerations relevant to transplant physicians, including donor screening in suspected germline predisposition, conditioning regimen selection, immune vulnerability following cord blood transplantation, and the management of severe post-transplant complications. These insights may inform clinical decision-making in similar pediatric settings, even as larger pediatric cohorts are needed.